4-N-[2-(diethylamino)ethyl]-2-iodo-1-N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]benzene-1,4-dicarboxamide | 1013658-05-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 4-N-[2-(diethylamino)ethyl]-2-iodo-1-N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]benzene-1,4-dicarboxamide
• CAS: 1013658-05-3
• 化学式: C₃₂H₅₂IN₅O₅
• 分子量: 713.7
• InChiKey: DFTCPNXLQSJFGQ-WIRXVTQYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.3
• 重原子数：
  43
• 可旋转键数：
  19
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.66
• 拓扑面积：
  137
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N⁴-(2-(diethylamino)ethyl)-2-iodo-N¹-(1-(1-(1-(methoxy(methyl)amino)-4-methyl-1-oxopentan-2-ylamino)-4-methyl-1-oxopentan-2-ylamino)-4-methyl-1-oxopentan-2-yl)terephthalamide 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 以48%的产率得到4-N-[2-(diethylamino)ethyl]-2-iodo-1-N-[(2S)-4-methyl-1-[[(2S)-4-methyl-1-[[(2S)-4-methyl-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]benzene-1,4-dicarboxamide
  参考文献：
  名称：

  Synthesis, Radiosynthesis, and Biological Evaluation of New Proteasome Inhibitors in a Tumor Targeting Approach

  摘要：

  Proteasome inhibition is a new strategy in cancer therapy. We synthesized three new peptide aldehyde inhibitors linked to the benzamide derivative structure to use their cytotoxic activity against malignant melanoma cells. Of these, 10 displayed the highest cytotoxicity (0.18 +/- 0.16 mu M). A radiosynthesis of the iodine aldehyde was performed. Its drug biodistribution showed that some selectivity of the benzamide group toward malignant melanoma tissue was conserved.

  DOI：

  10.1021/jm701419g

文献信息

• Synthesis, Radiosynthesis, and Biological Evaluation of New Proteasome Inhibitors in a Tumor Targeting Approach
  作者：Magali Vivier、Maryse Rapp、Janine Papon、Pierre Labarre、Marie-Josephe Galmier、Jacques Sauzière、Jean-Claude Madelmont

  DOI：10.1021/jm701419g

  日期：2008.2.1

  Proteasome inhibition is a new strategy in cancer therapy. We synthesized three new peptide aldehyde inhibitors linked to the benzamide derivative structure to use their cytotoxic activity against malignant melanoma cells. Of these, 10 displayed the highest cytotoxicity (0.18 +/- 0.16 mu M). A radiosynthesis of the iodine aldehyde was performed. Its drug biodistribution showed that some selectivity of the benzamide group toward malignant melanoma tissue was conserved.